{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:06:45Z","timestamp":1789646805266,"version":"4.0.0"},"reference-count":6,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Overview of:<\/jats:bold>\nEtminan M, Rezaeianzadeh R, Kezouh A, et al. Association between sublingual buprenorphine-naloxone exposure and dental disease. JAMA. 2022;328:2269-71.\n<\/jats:p>","DOI":"10.1136\/dtb.2023.000034","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T13:40:56Z","timestamp":1687527656000},"page":"115-115","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Dental adverse effects of sublingual buprenorphine and naloxone"],"prefix":"10.1136","volume":"61","member":"239","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"2025082623503233000_61.8.115.1","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2022.17485","article-title":"Association between Sublingual buprenorphine-naloxone exposure and dental disease","volume":"328","author":"Etminan","year":"2022","journal-title":"JAMA"},{"key":"2025082623503233000_61.8.115.2","unstructured":"Joint Formulary Committee . British national Formulary. 2023. Available: https:\/\/bnf.nice.org.uk\/ [Accessed 13 Jun 2023]."},{"key":"2025082623503233000_61.8.115.3","unstructured":"Suboxone tablets 2mg\/0.5mg . Summary of Product Characteristics, GB. Indivior UK Limited, 2022."},{"key":"2025082623503233000_61.8.115.4","unstructured":"Suboxone 2 mg\/0.5 mg sublingual film . Summary of Product Characteristics, GB. Indivior UK Limited, 2022."},{"key":"2025082623503233000_61.8.115.5","unstructured":"US Food and Drug Administration . FDA WARNS about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. 2022. Available: https:\/\/www.fda.gov\/media\/155352\/download [Accessed 7 Jun 2023]."},{"key":"2025082623503233000_61.8.115.6","unstructured":"Indivior Inc . Highlights of Prescribing information. 2022. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022410s049lbl.pdf [Accessed 13 Jun 2023]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2023.000034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:50:38Z","timestamp":1756277438000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2023.000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":6,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,7,26]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/dtb.2023.000034"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2023.000034","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]}}}